Why Is GLSI Stock Rising Today?
Synopsis
Greenwich LifeSciences said its Phase III breast cancer immunotherapy trial, involving 250 patients, showed a recurrence rate of under 1% per year.
Greenwich LifeSciences Inc. (GLSI) shares gained more than 13% in Tuesday’s pre-market trade after the company announced that its immunotherapy trial has shown a continued reduction in the rate of recurrence of breast cancer.
Greenwich LifeSciences said its 250-patient Phase III breast cancer immunotherapy trial, FLAMINGO-01, showed an annual recurrence rate below 1%.
Retail sentiment on Stocktwits around Greenwich LifeSciences trended in the ‘extremely bullish’ territory with message volumes at ‘extremely high’ levels. GLSI was the top trending ticker on the platform at the time of writing.
Get updates to this story developing directly on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.